Shiraz Nephro-Urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Department of Otolaryngology, Otolaryngology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Sci Rep. 2024 Jul 30;14(1):17576. doi: 10.1038/s41598-024-68572-8.
Hearing impairment in patients with chronic kidney disease (CKD), can affect the quality of life. At present, hearing dysfunction does not have an approved pharmacologic therapy. This study aimed to investigate the protective effects and possible mechanisms of curcumin as a therapeutic agent on hearing impairment in patients with chronic kidney disease. We conducted a randomized controlled trial of 40 chronic kidney disease patients not on dialysis with hearing impairment. Participants were randomly divided into two groups. One group received curcumin daily and the other received a placebo for 12 weeks. The interval between III and V waves, latency of wave V, auditory brain stem response (ABR) threshold, speech reception threshold (SRT), and speech discrimination score (SDS) were evaluated and analyzed before and after the intervention. After treatment, in the curcumin group, III-V waves interval and the latency of wave V were significantly reduced (P value < 0.0001), also ABR threshold was demonstrated a significant improvement (P value < 0.0001). In the trial group, the SDS was increased (P = 0.001) and the SRT was attenuated (P < 0.0001). We had either significant deterioration due to the course of the disease or insignificant changes in the placebo group. Daily administration of curcumin, can significantly improve hearing impairment in CKD patients. Accordingly, curcumin should be considered as a therapeutic option for treating hearing impairment in patients with chronic kidney disease.
慢性肾脏病（CKD）患者的听力障碍会影响生活质量。目前，听力功能障碍尚无批准的药物治疗方法。本研究旨在探讨姜黄素作为一种治疗药物对慢性肾脏病患者听力障碍的保护作用及其可能机制。我们对 40 名未接受透析的慢性肾脏病伴听力障碍患者进行了一项随机对照试验。参与者被随机分为两组。一组每天服用姜黄素，另一组服用安慰剂 12 周。在干预前后评估和分析了 III 波和 V 波之间的间隔、波 V 的潜伏期、听觉脑干反应（ABR）阈值、言语接受阈值（SRT）和言语辨别评分（SDS）。治疗后，姜黄素组 III-V 波间隔和波 V 潜伏期明显缩短（P 值<0.0001），ABR 阈值也明显改善（P 值<0.0001）。在试验组，SDS 增加（P=0.001），SRT 减弱（P<0.0001）。由于疾病的进程，我们要么出现了显著恶化，要么在安慰剂组中没有出现显著变化。每天服用姜黄素可显著改善 CKD 患者的听力障碍。因此，姜黄素可被视为治疗慢性肾脏病患者听力障碍的一种治疗选择。
